Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Haoqin Anti-cold Granules is a traditional Chinese medicine (TCM) candidate developed by Suzhou Yusen New Drug Development Co., Ltd. for the treatment of acute upper respiratory tract infections (URTI) in children. The formulation is specifically designed to address the "wind-heat with dampness" syndrome, a common TCM classification for respiratory ailments characterized by fever, sore throat, and dampness-related symptoms. It is currently undergoing Phase II clinical evaluation in China (Trial ID: CTR20240277) to assess its efficacy and safety in pediatric patients aged 3 to 12 years. As a multi-component herbal granule, it aims to provide a standardized therapeutic option for pediatric URTI within the framework of traditional medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao'er haoqin anti-cold granules.